Leo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"

Since spring, 133 Leo Pharma sales representatives have been at the ready to send tralokinumab to the US market. The wait has been spent on selling other products and learning from the eczema drug's launches in Europe. On Tuesday, the US approval finally arrived.
While Becki Morison, executive vice president responsible for Global Therapeutic & Value Strategy at Leo Pharma, is disappointed over the 8-month delay of tralokinumab, the wait has also had some benefits | Photo: Leo Pharma/PR
While Becki Morison, executive vice president responsible for Global Therapeutic & Value Strategy at Leo Pharma, is disappointed over the 8-month delay of tralokinumab, the wait has also had some benefits | Photo: Leo Pharma/PR
by ULRICH QUISTGAARD, translated by daniel pedersen

When the US Food and Drug Administration (FDA) approved of Leo Pharma's drug, tralokinumab, as a treatment for atopic dermatitis, the Danish firm's entire US-based sales organization was ready to push the launch button. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading